Active — Not RecruitingNot Applicable

Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

United States271 participantsStarted 2017-02-24

Plain-language summary

This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of pancreatic ductal adenocarcinoma * Signed initial informed consent * Participant agrees to genetic counseling Exclusion Criteria: * Prospective participant unable to sign informed consent based on referring physician recommendation. * Patient has neuroendocrine pancreatic tumor

What they're measuring

We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool

Timeframe: Up to 5 years

Trial details

NCT IDNCT03060720

SponsorDana-Farber Cancer Institute

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-04-07

View on ClinicalTrials.gov More Pancreatic Cancer trials